Fasting or Fed condition (Canada) [Design Issues]

posted by ElMag – 2012-02-22 17:23 (4436 d 15:02 ago) – Posting: # 8154
Views: 2,996

Hello!

It's been a while since my last query...so here I am again!

We would like to conduct a BE study in order to file our product in Canada, but we face a dilemma in the BE design. According to the already approved PIL of the Canadian reference product, the drug should be taken by mouth during a meal and with a large glass of water, while in the SmPC it is clearly stated that there are no clinically relevant differences in absorption when the reference product was administered either with food or in the fasting state. Keeping in mind that the Canadian Health Authority recommends BE studies under fed conditions only for specific categories of products (Guidance for Industry: Bioequivalence Requirements: Comparative Bioavailability Studies Conducted in the Fed State (2005)), we were of the opinion of conducting a BE study under fasting condition, while our Canadian CRO was of the opposite opinion. So, can you please share with us your point of view on the design? :ponder:


Thank you in advance for your assistance!


Edit: Subject line extended, document linked. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,984 posts in 4,822 threads, 1,651 registered users;
43 visitors (0 registered, 43 guests [including 6 identified bots]).
Forum time: 09:26 CEST (Europe/Vienna)

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5